Veracyte Inc Stock News

Veracyte is in an envious position for any company — it's profitable. Veracyte stock has rocketed more than 55% this year.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte's Decipher Prostate Test is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines.

Cancer diagnostics firm Veracyte has just sparked a breakout. That's just one reason to watch this AI-fueled growth stock.

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024. "The strong momentum across our testing business continued during the third quarter as we delivered record revenue along with profitability and cash generation,” said Marc Stapley, Veracyte's chief executive officer. “Looking ahead, we see...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. UBS Healthcare Conference – Rancho Palos Verdes, CA Fireside Chat on November 12th at 2:45 p.m. Eastern Time Guggenheim Inaugural Healthcare Innovation Conference – Boston, MA Fireside Chat on November 13th a...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer.